These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 22772543)

  • 21. [Clinical experience with xigris].
    Wyncoll D
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():46-7. PubMed ID: 15359944
    [No Abstract]   [Full Text] [Related]  

  • 22. [Xigris and corticoids: what are the perspectives for the patient with severe sepsis?].
    Annane D
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():43-5. PubMed ID: 15359943
    [No Abstract]   [Full Text] [Related]  

  • 23. Long-term cost effectiveness of drotrecogin alfa (activated): an unanswered question.
    Banks SM; Gerstenberger E; Eichacker PQ; Natanson C
    Crit Care Med; 2003 Jan; 31(1):308-9. PubMed ID: 12545035
    [No Abstract]   [Full Text] [Related]  

  • 24. Managing high-cost biotechnology products.
    Wong DH; Yang P
    Am J Health Syst Pharm; 2003 Jun; 60(12):1213-6. PubMed ID: 12845915
    [No Abstract]   [Full Text] [Related]  

  • 25. Treating severe sepsis with drotrecogin alfa (activated).
    Wyncoll D
    Hosp Med; 2003 Mar; 64(3):168-72. PubMed ID: 12669484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activated protein C (Xigris) treatment in sepsis: a drug in trouble.
    Gårdlund B
    Acta Anaesthesiol Scand; 2006 Sep; 50(8):907-10. PubMed ID: 16923083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant human activated protein C (Xigris).
    Levi M; De Jonge E; van der Poll T
    Int J Clin Pract; 2002 Sep; 56(7):542-5. PubMed ID: 12296618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation.
    Green C; Dinnes J; Takeda A; Shepherd J; Hartwell D; Cave C; Payne E; Cuthbertson BH
    Health Technol Assess; 2005 Mar; 9(11):1-126, iii-iv. PubMed ID: 15774234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drotrecogin alfa: a new approach in the treatment of severe sepsis.
    Vincent JL
    Expert Opin Biol Ther; 2002 Aug; 2(6):659-64. PubMed ID: 12171509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Local treatment pattern versus trial-based data: a cost-effectiveness analysis of drotrecogin alfa (activated) in the treatment of severe sepsis in Sweden.
    Hjelmgren J; Persson U; Tennvall GR
    Am J Ther; 2005; 12(5):425-30. PubMed ID: 16148428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Xigris--activated protein C].
    Tønnesen EK
    Ugeskr Laeger; 2004 Mar; 166(11):1002-4. PubMed ID: 15049235
    [No Abstract]   [Full Text] [Related]  

  • 32. Should we treat severe sepsis with activated protein C?
    Mackillop A
    Hosp Med; 2003 May; 64(5):316. PubMed ID: 12789748
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment of severe sepsis with Xigris: implications for the clinical nurse specialist.
    Powers J; Jacobi J
    Clin Nurse Spec; 2003 May; 17(3):128-30. PubMed ID: 12792186
    [No Abstract]   [Full Text] [Related]  

  • 34. Drotrecogin alpha (activated).
    Labbos J; Bradsher J; Kirkpatrick P
    Nat Rev Drug Discov; 2003 Jan; 2(1):13-4. PubMed ID: 12521028
    [No Abstract]   [Full Text] [Related]  

  • 35. Management of sepsis in the critically ill patient: key aspects.
    Vincent JL
    Expert Opin Pharmacother; 2006 Oct; 7(15):2037-45. PubMed ID: 17020431
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Should health care money in South Africa be spent on drotrecogin alfa?
    Taylor B; Burns D; van de Wal BW; MBewu T; Keeton GR
    S Afr Med J; 2003 Jul; 93(7):500-1. PubMed ID: 12939917
    [No Abstract]   [Full Text] [Related]  

  • 37. Prescribing indications based on successful clinical trials in sepsis: a difficult exercise.
    Carlet J
    Crit Care Med; 2006 Feb; 34(2):525-9. PubMed ID: 16424736
    [No Abstract]   [Full Text] [Related]  

  • 38. Management challenge with drotrecogin alfa (activated).
    Vanscoy GJ
    Am J Health Syst Pharm; 2002 Feb; 59 Suppl 1():S23-9. PubMed ID: 11885411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How to ENHANCE our knowledge of activated protein C during pediatric sepsis trials: pediatric versus adult trials.
    Hazelzet JA
    Pediatr Crit Care Med; 2006 May; 7(3):277-8. PubMed ID: 16682888
    [No Abstract]   [Full Text] [Related]  

  • 40. Drotrecogin alfa: a role in emergency department treatment of severe sepsis?
    McLeay AM
    Emerg Med Australas; 2004 Aug; 16(4):324-35. PubMed ID: 15283720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.